Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + everolimus + panitumumab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy that simultaneously inhibits three important pathways in cancer: VEGF (via bevacizumab), mTOR (via everolimus), and EGFR (via panitumumab). Preclinical data suggested that concurrent inhibition of these pathways may augment antitumor and antiangiogenic effects compared to inhibition of each pathway alone. The recommended phase II dose established in clinical trials is everolimus at 5 mg three times weekly plus panitumumab at 4.8 mg/kg and bevacizumab at 10 mg/kg every 2 weeks.
- Other names
- BEP
02
Targets
EGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on bevacizumab + everolimus + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + everolimus + panitumumab.